Company news

PYC Therapeutics Limited news in 2023

PYC Therapeutics Limited's news releases, calls and decks from 2023, newest first.

View company

RP11 Clinical Trial Progressing To High Dose Cohort

December 17, 2023

Response to Price Query

November 30, 2023

Supplementary Information

November 16, 2023

New Drug For Major Kidney Disease Effective In Human Models

November 12, 2023

PYC and FDA Align On Clinical Trial Pathway in ADOA

November 5, 2023

RP11 Clinical Trial Dosing Completed In Patient Cohort 2

November 2, 2023

PYC-001 Effective In Both NHPs and Patient-Derived Models

October 3, 2023

Safety Review Committee Approves Dose Escalation

September 21, 2023

RP11 Clinical Trial Dosing Completed In Patient Cohort 1

August 17, 2023

PYC Increases Ownership of VP-001 Program

August 9, 2023

PYC Receives FDA Fast Track Designation

August 1, 2023

Successful Toxicology Results Pave Way for Phase 2 Trial

July 17, 2023

First patient dosed in eye disease clinical trial

June 29, 2023

Placement Supporting Document

May 11, 2023

Successful Completion of $30m Placement

May 10, 2023

Commencement of First Clinical Study in RP11

April 25, 2023

Second Drug Program Progressing to Human Trials

April 3, 2023

FDA Clears PYC to Commence First Human Trials in RP11

March 5, 2023

VP-001 IND Lodgement

February 1, 2023

Decks in 2023